Bioventus (NYSE:BVS) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Bioventus (NYSE:BVS - Free Report) in a research report report published on Monday morning, Marketbeat reports. The firm issued an overweight rating and a $12.00 target price on the stock.

A number of other equities research analysts also recently issued reports on BVS. Craig Hallum set a $15.00 price objective on shares of Bioventus and gave the stock a "buy" rating in a research note on Wednesday, May 7th. Canaccord Genuity Group reiterated a "buy" rating and set a $15.00 price target on shares of Bioventus in a research report on Monday, March 17th.

Bioventus Price Performance

Shares of NYSE BVS traded down $0.20 during mid-day trading on Monday, reaching $6.82. The company had a trading volume of 428,692 shares, compared to its average volume of 431,357. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. Bioventus has a one year low of $5.73 and a one year high of $14.38. The firm has a market cap of $560.22 million, a price-to-earnings ratio of -11.18 and a beta of 0.84. The business's 50-day simple moving average is $6.72 and its 200 day simple moving average is $8.60.

Insider Activity

In other news, CFO Mark Leonard Singleton sold 3,875 shares of Bioventus stock in a transaction on Friday, April 11th. The stock was sold at an average price of $7.57, for a total value of $29,333.75. Following the transaction, the chief financial officer owned 141,088 shares in the company, valued at approximately $1,068,036.16. This trade represents a 2.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 33.00% of the company's stock.

Hedge Funds Weigh In On Bioventus

Hedge funds and other institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its stake in shares of Bioventus by 106.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company's stock valued at $36,000 after purchasing an additional 1,786 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Bioventus by 3,228.7% in the 1st quarter. GAMMA Investing LLC now owns 5,792 shares of the company's stock valued at $53,000 after purchasing an additional 5,618 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Bioventus by 23,761.5% in the 1st quarter. Russell Investments Group Ltd. now owns 6,204 shares of the company's stock valued at $57,000 after purchasing an additional 6,178 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Bioventus during the 4th quarter valued at $75,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Bioventus during the 4th quarter valued at $103,000. Institutional investors own 62.94% of the company's stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.